



**Creo Medical Group plc**  
("Creo" the "Company" or the "Group")

**Roll-out of Speedboat® UltraSlim reaches Asia Pacific**

*The controlled market release has seen the device used in the UK, USA, LATAM and now APAC since launch in December 2023*

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, announces continued progress on the phased market release of its latest device, Speedboat® UltraSlim, which has now been successfully used in the Asia Pacific region ("APAC") for the first time.

Speedboat® UltraSlim was used at the Prince of Wales Hospital Hong Kong in late January, where Dr. Hon Chi Yip and Dr. Simon Chu performed several procedures to treat precancerous lesions in the colon and stomach.

Since December 2023 Speedboat® UltraSlim has been successfully used in multiple clinical applications and in multiple jurisdictions: the UK, USA, LATAM and now APAC, as well as expanding indications treating different disease states and conditions. The device has been used to treat precancerous lesions in the colon, oesophagus and stomach as well as during procedures to surgically correct gastric and oesophageal abnormalities to help patients with swallowing and acid reflux disorders. In all cases these procedures help move patients from operating theatre procedures to endoscopic procedures with the inherent reduced impact on the patient and associated costs.

**Dr. Hon Chi Yip, Assistant Professor at the Division of Upper Gastrointestinal and Metabolic Surgery, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong said:** *"The new Speedboat® UltraSlim allows for use with a broader range of endoscopes, providing better access and handling. The performance of the advanced energy has increased the efficiency of the procedure."*

**Craig Gulliford, Chief Executive Officer of Creo Medical, said:** *"We're very pleased that Speedboat® UltraSlim has now reached the Asia Pacific region, representing tremendous progress with the phased initial market release in a short period of time. The team have done a terrific job with the regional regulatory steps necessary to enable this limited market release programme and we are excited to extend the roll-out to reach all of our customers in the coming months. APAC represents the fourth continent where the device has now been used in clinic and along with Dr. Hon Chi Yip and Dr. Simon Chu, we have had fantastic feedback from all customers who have so far had access to the new technology."*

**Enquiries:**

**Creo Medical Group plc**

Richard Rees (CFO)

[www.creomedical.com](http://www.creomedical.com)

+44 (0)1291 606 005

**Cavendish Capital Markets Limited**

Stephen Keys / Camilla Hume (NOMAD)

Michael Johnson (Sales)

+44 (0)20 7220 0500

**Deutsche Numis (Joint Broker)**

Freddie Barnfield / Duncan Monteith / Euan Brown

+44 (0)20 7260 1000

**Walbrook PR Ltd**

Paul McManus / Sam Allen /

Phillip Marriage

Tel: +44 (0)20 7933 8780 or [creo@walbrookpr.com](mailto:creo@walbrookpr.com)

Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 / +44 (0)7867 984 082

**About Creo Medical**

Creo is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation, and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive and more cost-efficient option for procedures.

For more information, please refer to the website [www.creomedical.com](http://www.creomedical.com)

**About Speedboat® UltraSlim**

Speedboat® UltraSlim is the third device in Creo's Speedboat® family of products, and is targeting the therapeutic treatment of disease in the GI tract (including cancer of the Bowel, Stomach and Oesophagus) as well as surgical procedures to deal

with abnormalities resulting in swallowing disorders and, in some cases, gastric reflux. This latest generation Speedboat has broad application in the GI tract due to a smaller configuration, ensuring compatibility with a wide range of colonoscopes and gastroscopes.

Powered by Creo's CROMA advanced energy platform, Speedboat® UltraSlim delivers fluid as well as advanced bipolar RF energy for controlled cutting and high frequency MW energy for controlled coagulation of tissue in the GI tract. The device is the culmination of a long programme of work to further miniaturise Creo's technology, and is compatible with the working channel of all commercially available endoscopes accessing the vast majority of GI endoscopic procedures.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@lse.com](mailto:ms@lse.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAWPUCCGUPCGPU